Alcobra announces plans to price public offering of ordinary stock

Stifel and Aegis Capital to be joint bookrunning managers for deal

By Devika Patel

Knoxville, Tenn., Oct. 15 - Alcobra Ltd. plans to conduct a public offering of its ordinary stock with a 45-day over-allotment option, according to a Form F-1 filed Tuesday with the Securities and Exchange Commission.

Stifel and Aegis Capital Corp. are the joint bookrunning managers.

Proceeds will be used for clinical trials, working capital and general corporate purposes.

The emerging biopharmaceutical company is based in Tel Aviv, Israel.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.